Article in ACS infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
5 citing papers in PubMed, 8 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
17 authors at 6 institutions in 2 countries.
Monica J BohmerDivision of Molecular Microbiology, Burnett School of Biomedical Sciences, University of Central Florida, Orlando, Florida 32826, United States.ORCID 0000-0003-1878-6200
Jinhua WangDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02215, United States.
Eva S IstvanDivision of Infectious Diseases, Department of Medicine and Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri 63110, United States.
Madeline R LuthDepartment of Pediatrics, School of Medicine, University California, San Diego, La Jolla, California 92093, United States.
Jennifer E CollinsDivision of Molecular Microbiology, Burnett School of Biomedical Sciences, University of Central Florida, Orlando, Florida 32826, United States.ORCID 0000-0002-1195-4630
Edward L HuttlinDepartment of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115, United States.ORCID 0000-0002-1822-1173
Lushun WangDepartment of Chemical and Systems Biology, ChEM-H, Stanford Cancer Institute, School of Medicine, Stanford University, Stanford, California 94305, United States.ORCID 0000-0002-8373-2199
Nimisha MittalDepartment of Pediatrics, School of Medicine, University California, San Diego, La Jolla, California 92093, United States.
Mingfeng HaoDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02215, United States.
Nicholas P KwiatkowskiDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02215, United States.
Steven P GygiDepartment of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115, United States.ORCID 0000-0001-7626-0034
Ratna ChakrabartiDivision of Cancer Research, Burnett School of Biomedical Sciences, University of Central Florida, Orlando, Florida 32826, United States.
Xianming DengSchool of Life Sciences, Xiamen University, Xiamen, Fujian 361102, China.ORCID 0000-0002-9354-5864
Daniel E GoldbergDivision of Infectious Diseases, Department of Medicine and Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri 63110, United States.ORCID 0000-0003-3529-8399
Elizabeth A WinzelerDepartment of Pediatrics, School of Medicine, University California, San Diego, La Jolla, California 92093, United States.ORCID 0000-0002-4049-2113
Nathanael S GrayDepartment of Chemical and Systems Biology, ChEM-H, Stanford Cancer Institute, School of Medicine, Stanford University, Stanford, California 94305, United States.ORCID 0000-0001-5354-7403
Debopam ChakrabartiDivision of Molecular Microbiology, Burnett School of Biomedical Sciences, University of Central Florida, Orlando, Florida 32826, United States.ORCID 0000-0002-4554-3119
Harvard University · USUniversity of Central Florida · USUniversity of California San Diego · USStanford University · USWashington University in St. Louis · USXiamen University · CN
Funding
Training Program in Basic Clinical GeneticsT32GM008666 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HAMILTON, BRUCE A · 1998 to 2021
$8.6M
Plasmodium Protein Kinase Focused Antimalarials DiscoveryR01AI172066 · NIAID · UNIVERSITY OF CENTRAL FLORIDA · PI DEBOPAM CHAKRABARTI, NATHANAEL Schiander GRAY · 2022 to 2026
$3.9M
Illumina NovaSeq 6000 Sequencing SystemS10OD026929 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JEPSEN, KRISTEN LYNN · 2019 to 2019
Protein kinases have proven to be a very productive class of therapeutic targets, and over 90 inhibitors are currently in clinical use primarily for the treatment of cancer. Repurposing these inhibitors as antimalarials could provide an accelerated path to drug development. In this study, we identified BI-2536, a known potent human polo-like kinase 1 inhibitor, with low nanomolar antiplasmodial activity. Screening of additional PLK1 inhibitors revealed further antiplasmodial candidates despite the lack of an obvious orthologue of PLKs in
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Human Polo-like Kinase Inhibitors as Antiplasmodials. · full record | Socratic